NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis $11.89 -0.14 (-1.16%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$11.60 -0.29 (-2.44%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Q32 Bio Stock (NASDAQ:QTTB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Q32 Bio alerts:Sign Up Key Stats Today's Range$11.59▼$12.5550-Day Range$4.92▼$14.0052-Week Range$1.35▼$14.85Volume628,055 shsAverage Volume1.58 million shsMarket Capitalization$201.65 millionP/E Ratio4.47Dividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company Overview Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. Read More Q32 Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreQTTB MarketRank™: Q32 Bio scored higher than 88% of companies evaluated by MarketBeat, and ranked 46th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingQ32 Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialQ32 Bio has a consensus price target of $13.50, representing about 13.5% upside from its current price of $11.89.Amount of Analyst CoverageQ32 Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Q32 Bio's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($1.96) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is 4.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is 4.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.50.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Q32 Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.47% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 0.31, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Q32 Bio has recently increased by 36.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. News and Social Media4.0 / 5News SentimentN/A News SentimentQ32 Bio has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Q32 Bio this week, compared to 2 articles on an average week.Search Interest10 people have searched for QTTB on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. Company Ownership4.7 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Q32 Bio in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $30,000,000.00 in company stock, which represents 14.8769% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders40.00% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QTTB Stock News HeadlinesQ32 Bio (NASDAQ:QTTB) Director Diyong Xu Buys 1,875,000 SharesJune 3, 2026 | americanbankingnews.comQ32 Bio Inc. Stock (QTTB) Opinions on Massive Price SurgeJune 2, 2026 | quiverquant.comQGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 10 at 1:00 AM | Behind the Markets (Ad)Q32 Bio (NASDAQ:QTTB) Director Orbimed Advisors Llc Buys 1,875,000 SharesJune 2, 2026 | insidertrades.comQ32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data CatalystsMay 28, 2026 | seekingalpha.comQTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month – What’s Driving The Investor Optimism?May 27, 2026 | finance.yahoo.comQ32 Bio secures $55 million private placement to advance alopecia areata pipeline (QTTB)May 27, 2026 | msn.comQ32 Bio Raises $55 Million in Private PlacementMay 27, 2026 | tipranks.comSee More Headlines QTTB Stock Analysis - Frequently Asked Questions How have QTTB shares performed this year? Q32 Bio's stock was trading at $3.32 at the start of the year. Since then, QTTB stock has increased by 258.1% and is now trading at $11.89. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) issued its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.14. When did Q32 Bio IPO? Q32 Bio (QTTB) raised $135 million in an initial public offering on Wednesday, March 28th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Who are Q32 Bio's major shareholders? Q32 Bio's top institutional investors include Renaissance Technologies LLC (1.22%), ADAR1 Capital Management LLC (0.21%) and Cetera Investment Advisers (0.12%). Insiders that own company stock include Diyong Xu, Orbimed Advisors Llc, Jodie Pope Morrison, Shelia M Violette and Paul Alloway. View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Q32 Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/05/2026Today6/10/2026AGM 20266/12/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 QTTB's financial health is in the Green zone, according to TradeSmith. QTTB has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Price Target for Q32 Bio$13.50 High Price Target$14.00 Low Price Target$13.00 Potential Upside/Downside+13.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$2.66 Trailing P/E Ratio4.47 Forward P/E RatioN/A P/E GrowthN/ANet Income$29.82 million Net MarginsN/A Pretax Margin61.86% Return on Equity149.23% Return on Assets34.50% Debt Debt-to-Equity Ratio0.04 Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual Sales$53.74 million Price / Sales3.75 Cash Flow$1.50 per share Price / Cash Flow7.93 Book Value$3.41 per share Price / Book3.49Miscellaneous Outstanding Shares16,960,000Free Float10,174,000Market Cap$201.65 million OptionableN/A Beta0.27 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:QTTB) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
